GGGiacomo Gazzano

Giacomo Gazzano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giacomo Gazzano has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA

    by Claudia Moneta, Matteo Trevisan, Carla Colombo, Alessia De Luca, Marina Lugaresi, Giacomo Maria Reali, Giacomo Gazzano, Luca Persani, Laura Fugazzola, Simone De Leo

    Context: The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting. Design: Retrospective observational study Setting: Tertiary care center Patients: Data from 670 PTC patients with complete histopathological and final disease outcome were included. Main Outcome measures: We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction. Results: The reclassification according to the 2025 ATA risk stratification showed that the proportion of “low-risk” PTC decreased by 22.2%, while “intermediate-risk” and “high-risk” PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the two stratification systems revealed that structural disease persistence in the 2025 “low-risk” and “high-risk” classes was comparable. The 2025 “intermediate-high-risk” class was similar to the former “intermediate-risk” class, whereas the “low-intermediate-risk” class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 “low-risk” class (p = 0.003), but lower than that of the 2015 “intermediate-risk” class (p = 0.012). Conclusions: In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined “low-intermediate-risk” class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior “low-risk” and “intermediate-risk” classes, highlighting the need for dedicated prospective studies to address proper management of this newly-defined group of patients.


  • TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer

    by Valentina Cirello, Carla Colombo, Delfina Tosi, Alessandro Manzo, Maria Orietta Borghi, Umberto Gianelli, Giacomo Gazzano, Stefano Ferrero, Gianlorenzo Dionigi, Luca Persani, et al.

    Context: No data are available about the possible association of TP53 mutations and the response to multikinase inhibitors (MKIs) in thyroid cancer (TC). Objective: We evaluated the effect of TP53 mutations on the response to lenvatinib (LEN) in advanced TCs and in vitro models. Methods: We investigated the molecular profile, including TP53 mutations, of 30 tumor tissues from patients treated with LEN, and tested p53 status by immunohistochemistry. These data were compared with clinical-pathological features, and tumor response to LEN. The response to LEN was also evaluated in TP53-defective and TP53-proficient TC cell lines. Results: TP53 mutations significantly correlated with a poor response to LEN (P = .005). TP53-mutated patients had a shorter progression-free survival (PFS) (P < .0001) and overall survival (OS) rates (P = .0007). Accordingly, patients harboring altered nuclear p53 protein expression had shorter PFS and OS (P = .0001 and P = .0056, respectively). These data were confirmed in a validation cohort. In accordance with clinical data, TC cell lines with p53 alterations had low or null sensitivity, while those with TP53 wild-type showed different degrees of sensitivity, primarily due to the increased number of tumor cells in G1 phase, consistent with the cytostatic effect of LEN. Conclusion: We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and is associated with worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included in the patient/tumor characterization to be performed before starting an MKI treatment.


  • Open Access

    Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model

    by Viola Ghiandai, Elisa Stellaria Grassi, Giacomo Gazzano, Laura Fugazzola, Luca Persani

    Background: Thyroid cancer (TC) is the most common endocrine malignancy. Nowadays, undifferentiated thyroid cancers (UTCs) are still lethal, mostly due to the insurgence of therapy resistance and disease relapse. These events are believed to be caused by a subpopulation of cancer cells with stem-like phenotype and specific tumor-initiating abilities, known as tumor-initiating cells (TICs). A comprehensive understanding of how to isolate and target these cells is necessary. Here we provide insights into the role that the protein Epithelial Cell Adhesion Molecule (EpCAM), a known TICs marker for other solid tumors, may have in TC biology, thus considering EpCAM a potential marker of thyroid TICs in UTCs. Methods: The characterization of EpCAM was accomplished through Western Blot and Immunofluorescence on patient-derived tissue samples, adherent cell cultures, and 3D sphere cultures of poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) cell lines. The frequency of tumor cells with putative tumor-initiating ability within the 3D cultures was assessed through extreme limiting dilution analysis (ELDA). EpCAM proteolytic cleavages were studied through treatments with different cleavages’ inhibitors. To evaluate the involvement of EpCAM in inducing drug resistance, Vemurafenib (PLX-4032) treatments were assessed through MTT assay. Results: Variable EpCAM expression pattern was observed in TC tissue samples, with increased cleavage in the more UTC. We demonstrated that EpCAM is subjected to an intense cleavage process in ATC-derived 3D tumor spheres and that the 3D model faithfully mimics what was observed in patient’s samples. We also proved that the integrity of the protein appears to be crucial for the generation of 3D spheres, and its expression and cleavage in a 3D system could contribute to drug resistance in thyroid TICs. Conclusions: Our data provide novel information on the role of EpCAM expression and cleavage in the biology of thyroid TICs, and our 3D model reflects the variability of EpCAM cleavage observed in tissue samples. EpCAM evaluation could play a role in clinical decisions regarding patient therapy since its expression and cleavage may have a fundamental role in the switch to a drug-resistant phenotype of UTC cells.


  • Somatic mutational analysis of DAX1 in testes from men with idiopathic azoospermia

    by Giovanna Mantovani, Mario Mancini, Giacomo Gazzano, Anna Spada, Giovanni M. Colpi, Paolo Beck-Peccoz, Luca Persani